CD8A and neoplasm: We first explored the cross-reactivity profile of human CD8 T cells recruited after vaccination with either the native or an affinity-optimized Melan-A/MART-126-35 peptide and found better control of potential escape epitopes by T cells isolated from patients vaccinated with the native tumor antigen.